TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06249815

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
Study: NCT06325748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SENTI-202
Description: SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.~SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles to achieve optimal response with the optionality of an additional consolidation cycle thereafter. Additional dosing schedules may be explored depending on study data.
Study: NCT06328114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
Study: NCT05714813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Speed Circuit Resistance Training
Description: Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lecture on Diet, Exercise and Cognition
Description: Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
Study: NCT04676646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Investigational medicinal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Investigational medicinal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained.
Study: NCT05360511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: particulate xenograft + erythropoietin gel.
Description: 1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: particulate xenograft
Description: * All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect.
Study: NCT05782608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ibuprofen
Description: Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketorolac
Description: Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
Study: NCT05061810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone application self-management programme
Description: The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone application self-management programme
Description: The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone application self-management programme
Description: The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
Study: NCT05817188

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was applied
Study: NCT06314568

Intervention type: RADIATION
Intervention: Radiochemotherapy plus interventional radiotherapy
Description: All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
Study: NCT06117150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting Coronary Spur Stent System
Description: All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
Study: NCT06328114

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
Study: NCT06495918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: Intravitreal Injection of OTX-TKI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection of 2mg of aflibercept

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Intravitreal Injection of 8mg of aflibercept
Study: NCT05303792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05028933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPCAM CAR-T
Description: Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
Study: NCT06117215

Intervention type: OTHER
Intervention: Data collection
Description: data collection
Study: NCT05303792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Given IV
Study: NCT06384274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
Study: NCT06159205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard exercises
Description: Standard exercises for TKA patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard exercises
Description: Standard exercises for TKA patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: Core stability exercises for TKA patients.
Study: NCT05460273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan (Dato-DXd)
Description: Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
Study: NCT05408507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC123 Framework
Description: This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
Study: NCT04942340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atipamezole & Caffeine
Description: In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride & Saline
Description: In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
Study: NCT05303792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study: NCT05653687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy
Description: Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
Study: NCT06295263

Intervention type: OTHER
Intervention: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers
Description: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups

Intervention type: OTHER
Intervention: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers
Description: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups

Intervention type: OTHER
Intervention: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers
Description: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups

Intervention type: OTHER
Intervention: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers
Description: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups

Intervention type: OTHER
Intervention: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers
Description: Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
Study: NCT05337007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: 48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate protein diet
Description: 48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
Study: NCT05519423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Incentive Program
Description: Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
Study: NCT05328882

Intervention type: OTHER
Intervention: Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation
Description: The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.

Intervention type: OTHER
Intervention: Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation
Description: The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
Study: NCT05611203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: An Oropharyngeal swab
Description: An Oropharyngeal swab performed for diagnostic purposes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: An Oropharyngeal swab
Description: An Oropharyngeal swab performed for diagnostic purposes
Study: NCT06339723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pecha Kucha
Description: Pecha Kucha Method training was given
Study: NCT05548231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05303792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study: NCT05373329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanvello (app)
Description: Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
Study: NCT05678309

Intervention type: OTHER
Intervention: Blood samples
Description: At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA

Intervention type: OTHER
Intervention: skin swab sample
Description: At inclusion a skin swab sample will be collected

Intervention type: OTHER
Intervention: skin biopsy sample
Description: At inclusion a skin biopsy sample will be collected
Study: NCT05303792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study: NCT05642325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Participants will receive vamikibart IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamikibart
Description: Participants will receive vamikibart IVT injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants will receive a sham procedure that mimics an IVT injection.
Study: NCT05130606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.
Description: Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FORCE Fact Sheet
Description: Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
Study: NCT06535308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 5 mg
Description: Korean / 3 on BnH-015B, 1 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 10 mg
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 20 mg
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg (Dietary impact)
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg
Description: Caucasian / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 80 mg
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 160 mg
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg (MAD)
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 80 mg (MAD)
Description: Korean / 6 on BnH-015B, 2 on placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 40 mg (Part II)
Description: Korean / 9 subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BnH-015B 80 mg (Part II)
Description: Korean / 9 subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BnH-015B Placebo (Part II)
Description: Korean / 6 subjects
Study: NCT05344378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATTAIN NAV Technology-Enhanced Family Navigation Model
Description: The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATTAIN NAV Technology-Enhanced Family Navigation Model
Description: The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATTAIN NAV Technology-Enhanced Family Navigation Model
Description: The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.